secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIODESIX INC (BDSX)
CIK:        0001439725
Form:       8-K
Filed at:   2022-03-14T23:59:59+00:00
Accession:  0000950170-22-003491
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biodesix reports FY2021 revenue $54.5M; core lung diagnostic up 49% YoY to $18.7M; net loss $43.2M
--------------------------------------------------------------------------------

- Q4 total revenue $7.2M; core lung diagnostic revenue $5.4M (+48% YoY); BioPharma services $1.4M (-29% YoY).
- FY2021 total revenue $54.5M; core lung diagnostic $18.7M (+49% YoY); COVID-19 testing revenue $30.2M (+7% YoY).
- Q4 gross margin 65% vs 46% YoY driven by mix shift to higher-margin lung diagnostics; operating expenses $16.4M.
- Net loss Q4 $13.3M (increase of 193% YoY); FY2021 net loss $43.2M (increase 38% YoY).
- Guides FY2022 total revenue $37.5M-$39.5M; cash $32.7M after $20M debt prepayment and $15.7M equity raise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439725/000095017022003491/0000950170-22-003491-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439725/000095017022003491/bdsx-20220314.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-003491

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer